Clin2
NCT06911827Possibly a fitRecruiting

Combination drug study for advanced solid tumor cancer

Advanced Solid Tumor

Treatments studied

Part of Cancer clinical trials.

This trial tests a combination of two new treatments (QLP2117 and QL2107) for people with advanced solid tumors that have not responded to standard therapy. The goal is to see if the combination can shrink tumors or slow cancer growth.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1/Phase 2
Enrollment
149 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • Your cancer has come back or hasn't responded to standard treatments, or there's no standard treatment available.
  • You have at least one tumor that can be measured on imaging scans (like CT or MRI).
  • You are able to do your daily activities with little or no help (ECOG score 0 or 1).
  • You are willing to provide a sample of your tumor tissue from a past biopsy or surgery.
  • You must not have an active autoimmune disease, an active infection, or have had a live vaccine in the past 30 days.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07256782Recruiting· Phase 1/Phase 2
A study of QLC5508 combinations for advanced solid tumors

This trial tests a new drug called QLC5508, given in combination with other treatments, for people with advanced solid tumors that have stopped responding to standard therapy or who haven't had treatment yet. The goal is to see if the combination can shrink tumors or slow their growth.

Shanghai
NCT06872580Not yet recruiting· Phase 1
Study of QLS1209 in advanced solid tumors

This trial tests an experimental drug, QLS1209, for people with advanced solid tumors that have specific genetic changes (CCNE1 amplification, FBXW7 mutation, or PPP2R1A mutation). It aims to see if the drug is safe and effective for those who have not responded to standard treatments or have no standard options.

NCT05830045Recruiting· Phase 1
Testing a new drug for advanced solid tumors

This Phase 1 trial studies QLP2117, a new treatment, in people with advanced solid tumors that have come back or didn’t respond to standard care. It mainly looks at safety and how the body handles the drug, and it may help find a dose worth further study.

Guangzhou
NCT07272590Not yet recruiting· Phase 1/Phase 2
QLC5513 combined with QL1706 for advanced solid tumors

This trial tests a new combination of drugs (QLC5513 and QL1706) for people with advanced or metastatic solid tumors that cannot be removed by surgery or radiation. The goal is to see if this combination is safe and effective.

NCT07061639Not yet recruiting· Phase 1/Phase 2
QLS5133 for advanced solid tumors

This trial tests a new drug called QLS5133 for people with advanced solid tumors that have not responded to other treatments. The drug is given alone, and the study aims to see if it is safe and effective.

Shanghai
NCT06932094Not yet recruiting· Phase 1
Testing QLS5132 for advanced solid tumors

This trial tests a new drug, QLS5132, for people with advanced solid tumors that have not responded to other treatments. The goal is to see if the drug is safe and effective.

Hangzhou

Hear when a new Advanced Solid Tumor trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.